Bill to remove prior authorization for many generics and time‑sensitive drugs draws broad clinical support, insurer objections

Representative Jonathan Karlen opened the hearing on House Bill 399, which would prohibit prior authorization for oral or inhaled non‑biologic generic prescription drugs and for certain time‑sensitive medications identified in the bill (for example, inhalers and insulin). The sponsor said he and negotiators accepted an amendment requested by payers excluding biologic and specialty medications (those defined using Medicare Part D and higher‑cost specialty definitions) to the carve‑out.

Why it matters: Supporters said prior authorization on inexpensive generics and essential, time‑sensitive drugs produces unnecessary delays that can result in emergency room visits, hospitalizations, or interruptions in chronic disease management. They urged the committee to remove what they described as red tape that produces downstream costs and harms.

Clinical testimony and examples: Clinicians from primary care, pediatrics,…